Sotera Health (NASDAQ:SHC) Issues Earnings Results

Sotera Health (NASDAQ:SHC) announced its quarterly earnings data on Thursday. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.02, FiscalAI reports. The firm had revenue of $321.38 million during the quarter, compared to analysts’ expectations of $309.70 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The company’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.20 EPS. Sotera Health updated its FY 2026 guidance to 0.950-1.010 EPS.

Here are the key takeaways from Sotera Health’s conference call:

• Strong second-quarter performance: Revenue rose 8% on a constant-currency basis, adjusted EBITDA increased 8.7%, margins expanded 36 basis points, and adjusted EPS grew 30% to $0.26.
• Sotera Health raised its 2026 outlook, now expecting constant-currency revenue growth of 5.25%-6.75%, adjusted EBITDA growth of 5.75%-7.25%, and adjusted EPS of $0.95-$1.01.
• Sterigenics delivered 7% constant-currency revenue growth, supported by pricing, volume and mix, while Nordion grew 16.7%; Sterigenics also expects second-half growth from favorable shutdown timing, a large customer outsourcing EO sterilization, and the new X-ray facility.
• Net leverage improved to 3.0 times, reaching the company’s long-term target range, while 2026 capital expenditures are expected at $200 million-$225 million for capacity expansions and facility upgrades; management expects a meaningful CapEx reduction in 2027.
• Nelson Labs’ revenue grew 5.4% in constant currency, but segment income margin declined year over year because of higher costs; management continues to forecast a full-year margin in the low-to-mid 30% range.

Sotera Health Price Performance

Shares of SHC traded down $0.05 during midday trading on Friday, hitting $18.86. The company’s stock had a trading volume of 3,375,782 shares, compared to its average volume of 3,027,352. The company has a quick ratio of 2.54, a current ratio of 2.80 and a debt-to-equity ratio of 3.19. Sotera Health has a one year low of $12.94 and a one year high of $19.85. The stock has a market capitalization of $5.38 billion, a price-to-earnings ratio of 33.09 and a beta of 1.77. The company’s fifty day simple moving average is $17.13 and its two-hundred day simple moving average is $16.33.

Trending Headlines about Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wall Street Zen cut Sotera Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. JPMorgan Chase & Co. upped their price objective on shares of Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Friday. Citigroup increased their price objective on shares of Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday. UBS Group set a $19.00 target price on shares of Sotera Health in a report on Wednesday, June 24th. Finally, Piper Sandler restated an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of Sotera Health in a research report on Friday. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Sotera Health has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Insider Buying and Selling at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $15.17, for a total value of $193,194,516.17. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 15.36% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC boosted its stake in shares of Sotera Health by 831.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company’s stock valued at $37,000 after purchasing an additional 2,935 shares in the last quarter. Wells Fargo & Company MN increased its position in Sotera Health by 736.5% during the 4th quarter. Wells Fargo & Company MN now owns 4,283 shares of the company’s stock worth $76,000 after purchasing an additional 3,771 shares in the last quarter. Quadrant Capital Group LLC acquired a new position in Sotera Health during the 3rd quarter worth approximately $86,000. Los Angeles Capital Management LLC bought a new position in Sotera Health in the 4th quarter valued at approximately $90,000. Finally, PNC Financial Services Group Inc. lifted its stake in Sotera Health by 10.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,204 shares of the company’s stock valued at $127,000 after purchasing an additional 705 shares during the last quarter. Institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.